Quest Diagnostics vs RadNet
DGX and RDNT side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How DGX and RDNT compare
Quest Diagnostics is the larger company, worth 4.7 times as much as RadNet ($28.6B against $6.0B).
RadNet grew revenue faster over the last twelve months (21.1% versus 9.1% for Quest Diagnostics).
Quest Diagnostics keeps more of each dollar of sales as profit, with a net margin of 9.5% compared with −0.94% at RadNet.
Quest Diagnostics pays a dividend yielding 1.3%; RadNet does not pay one.
Quest Diagnostics scores higher on the StockData Score (12 against 7 for RadNet), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | DGX | RDNT |
|---|---|---|
| Size and price | ||
| Market cap | $28.6B | $6.0B |
| Share price | $259.60 | $76.42 |
| Change, 1 year | 38.9% | 2.6% |
| Change, 5 years | 74.9% | 170% |
| Beta (5Y) | 0.32 | 1.15 |
| Employees | 57K | 76 |
| StockData Score | ||
| Total score | 12 (better) | 7 |
| Valuation score | 0 | 0 |
| Growth score | 2 | 2 |
| Performance score | 4 (better) | 2 |
| Health score | 3 | 3 |
| Dividend score | 3 (better) | 0 |
| Valuation | ||
| P/E | 25.9× | – |
| P/S | 2.4× (better) | 2.5× |
| P/B | 3.7× (better) | 5.4× |
| EV/EBITDA | 14.6× (better) | 27.4× |
| P/FCF | 20.8× | – |
| PEG | 8.19 | – |
| FCF yield | 4.8% | – |
| Fair value | $236.19 | $48.94 |
| Margin of safety | −9.9% (better) | −56.1% |
| Growth | ||
| Revenue growth (TTM) | 9.1% | 21.1% (better) |
| Revenue growth, 5Y average | 3.2% | 13.7% (better) |
| Net income growth (TTM) | 16.5% | – |
| EPS growth (TTM) | 18.3% | – |
| EPS growth, 5Y average | −3.5% | – |
| Profitability | ||
| Gross margin | 33.1% | – |
| Operating margin | 14.6% (better) | 3.1% |
| Net margin | 9.5% (better) | −0.94% |
| FCF margin | 11.6% | – |
| Return on equity | 15.2% (better) | −2.1% |
| Return on invested capital | 10.7% (better) | 2.8% |
| Financial health | ||
| Debt / equity | 0.73 (better) | 1.18 |
| Net debt / EBITDA | 2.06 (better) | 2.28 |
| Interest coverage | – | 1.0× |
| Current ratio | 1.70 (better) | 1.49 |
| Altman Z-score | 3.82 (better) | 1.94 |
| Piotroski F-score | 7 (better) | 3 |
| Dividends and buybacks | ||
| Dividend yield | 1.3% | – |
| Payout ratio | 32.7% | – |
| Shareholder yield | 1.3% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 95.4% | 104% |
| Held by insiders | 0.48% | 4.6% |
| Insider net buying, 12 months | −$33.5M | −$11.9M (better) |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 3.4% | 11.8% |
Go deeper
- DGX stock overview
- DGX income statement
- DGX valuation and score
- RDNT stock overview
- RDNT income statement
- RDNT valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.